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Introduction {#osp4166-sec-0006}
============

Youth with obesity who fail to improve their body mass index (BMI) via primary care clinic interventions should be referred to comprehensive multidisciplinary weight management programs [1](#osp4166-bib-0001){ref-type="ref"}. These multidisciplinary programs provide intensive lifestyle modification therapy and, when indicated, more aggressive treatments such as pharmacotherapy and bariatric surgery to improve weight status and obesity‐related comorbidities [1](#osp4166-bib-0001){ref-type="ref"}, [2](#osp4166-bib-0002){ref-type="ref"}. Although approximately one in five youths in the USA is afflicted with obesity [3](#osp4166-bib-0003){ref-type="ref"}, only a small fraction are treated in such multidisciplinary programs. Identification of specific health characteristics which differentiate youth with obesity who seek weight management treatment programs versus those who do not may shed light on underlying motivations for patients to seek such treatment. Furthermore, identification of the differential health characteristics of treatment‐seeking youth may have implications for access to such care and should inform the types of interventions provided by these multidisciplinary programs.

To date, only small studies have examined differences between population samples and treatment‐seeking samples of youth with obesity, and most of these have focused on rates of mental illness. Although most of these studies suggest that treatment‐seeking youth with obesity have higher rates of mental health disorders compared with population samples of youth with obesity [4](#osp4166-bib-0004){ref-type="ref"}, [5](#osp4166-bib-0005){ref-type="ref"}, [6](#osp4166-bib-0006){ref-type="ref"}, it is not known if these differences extend to cardiometabolic risk factors and other obesity‐related comorbidities. Accordingly, the aim of this study was to compare the cardiometabolic risk factor profiles between two large, contemporary cohorts of youth with obesity: a treatment‐seeking sample derived from the Pediatric Obesity Weight Evaluation Registry (POWER) [7](#osp4166-bib-0007){ref-type="ref"} and a population sample derived from the National Health and Nutrition Examination Survey (NHANES). Owing to the fact that comorbidities such as hypertension, impaired glucose tolerance and dyslipidemia are largely driven by degree of adiposity, it was hypothesized that treatment‐seeking and population samples of youth with obesity would have similarly high rates of cardiometabolic derangements when accounting for BMI.

Methods {#osp4166-sec-0007}
=======

Sample {#osp4166-sec-0008}
------

This cross‐sectional study compared two large contemporary cohorts of adolescents with obesity: an obesity treatment‐seeking sample and a population‐based sample. The treatment‐seeking cohort was obtained from the POWER. POWER, established in 2013, is an ongoing national registry of patients ≤18 years of age with obesity (age‐specific and sex‐specific BMI ≥95th percentile) who are seeking care in 1 of 27 multicomponent pediatric weight management clinics/programs from 20 states in the USA (ClinicalTrials.gov NCT02121132). The purpose of POWER is to identify the characteristics of patients and clinics/programs in order to identify variables that predict favorable outcomes. Program inclusion criteria include those that provide multicomponent pediatric weight management treatment for youth with obesity and that agree to collect the required data elements including patient height, weight, age, race and ethnicity. Each program was responsible for obtaining IRB approval. More information on the establishment of POWER is available elsewhere [7](#osp4166-bib-0007){ref-type="ref"}. POWER data for this study were collected from May 2014 through April 2016. All POWER sites endorsed this study. The population‐based cohort of youth with obesity was obtained from NHANES 2009--2010, 2011--2012 and 2013--2014 data cycles to utilize available data that best matched the duration when POWER data was collected while increasing the sample size. NHANES is a continuous annual survey of the US population\'s health that was started in 1999 and releases data to the public in 2‐year intervals [8](#osp4166-bib-0008){ref-type="ref"}. NHANES includes subject interviews, physical examinations and fasting laboratory evaluations.

From both samples, POWER and NHANES, participants were included if they were between 12 and 17 years of age, had obesity (age‐specific and sex‐specific BMI ≥95th percentile), and had at least one of the following outcomes measured: systolic blood pressure, diastolic blood pressure, total cholesterol (TC), LDL‐cholesterol (LDL‐c), HDL‐cholesterol (HDL‐c), triglycerides (TG), non‐HDL‐cholesterol (non‐HDL‐c), fasting glucose (FG), fasting insulin, and hemoglobin A1c (HbA1c). Participants missing all outcomes were excluded (43 from POWER and 11 from NHANES), as were those with glucose and/or HbA1c values consistent with diabetes.

Measures and definitions {#osp4166-sec-0009}
------------------------

Self‐reported age, race and ethnicity were collected from both POWER and NHANES, and for this study race and ethnicity were combined into one category. Height, weight and blood pressure were measured at the baseline visits to the weight management programs/clinics for the POWER cohort and by trained personnel in the NHANES cohort. Fasting lipid panel, FG, fasting insulin, HBA1c and ALT were collected at baseline or within 6 months prior to the baseline visits for the POWER sample and according to standard protocols for the NHANES sample. See Table [1](#osp4166-tbl-0001){ref-type="table-wrap"} for definitions of cut‐points for classes I, II and III obesity [9](#osp4166-bib-0009){ref-type="ref"}, elevated blood pressure [10](#osp4166-bib-0010){ref-type="ref"}, dyslipidemia [11](#osp4166-bib-0011){ref-type="ref"}, prediabetes, homeostasis model assessment‐insulin resistance (HOMA‐IR), and abnormal ALT [12](#osp4166-bib-0012){ref-type="ref"}.

###### 

Definitions of normal and abnormal measures of cardiometabolic variables

  ------------------------------------------------------------------------------------------------------
  Cardiometabolic variable   Cutoffs
  -------------------------- ---------------------------------------------------------------------------
  Obesity                    Class I BMI ≥100% of 95th percentile\
                             Class II BMI ≥120% of 95th percentile\
                             Class III BMI ≥140% of 95th percentile

  Blood pressure             Normal if SBP and DBP \< 90th percentile\
                             Pre‐HTN if SBP or DBP ≥90th and \< 95th percentile\
                             HTN if SBP or DBP ≥95th percentile

  Glucose                    Non‐diabetic if HbA1c \<5.7% and fasting glucose \<100 mg/dL\
                             Pre‐diabetic if HbA1c 5.7--6.4% or fasting glucose 100--125 mg/dL\
                             Diabetic if HbA1c ≥6.5% or fasting glucose ≥126 mg/dL

  LDL‐c                      Normal if LDL‐c \< 110 mg/dL\
                             Borderline High if LDL‐c 110--130 mg/dL\
                             High if LDL‐c ≥ 130 mg/dL

  Triglycerides              Normal if triglycerides \<90 mg/dL\
                             Borderline high if triglycerides 90--129\
                             High if triglycerides ≥130 mg/dL

  HDL‐c                      Normal if HDL‐c \> 45 mg/dL\
                             Borderline Low if HDL‐c 40--45 mg/dL\
                             Low if HDL‐c ≤ 40 mg/dL

  ALT                        Normal ALT \<25 U/L (males); \<22 U/L (female patients)\
                             Moderately elevated ALT 25--40 (male patients); 22--40 (female patients)\
                             Severely elevated if ALT ≥40 (male and female patients)
  ------------------------------------------------------------------------------------------------------

BMI, body mass index; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; HDL‐c, HDL‐cholesterol; LDL‐c, LDL‐cholesterol; SBP, systolic blood pressure.

Statistical analysis {#osp4166-sec-0010}
--------------------

To account for the complex, multilevel sampling structure of NHANES, sampling weights were provided for each individual with the data [8](#osp4166-bib-0008){ref-type="ref"}. Given the structure of POWER, there are no provided sampling weights, so equal sample weight was assumed for each subject. Sampling weights were normalized to sum to 1 within each study, and then normalized in the combined POWER/NHANES dataset by the proportion of data coming from each study. Descriptive characteristics of the POWER and NHANES cohorts were calculated with weighted mean (weighted SD) or weighted % to account for the weighted structure of the data. All analyses were conducted in R v3.3.1. [13](#osp4166-bib-0013){ref-type="ref"}. The survey package in R was used to take into account the weighted structure of the data for analyses for all linear and logistic regressions.

Results {#osp4166-sec-0011}
=======

The POWER cohort included 1,823 subjects and the NHANES cohort included 617. Demographics, BMI classifications and cardiometabolic variables are presented in Table [2](#osp4166-tbl-0002){ref-type="table-wrap"}. There was an equal distribution of sex, although the POWER sample had a lower proportion of white and privately insured participants. The POWER sample had more participants with classes II and III obesity, pre‐hypertension, hypertension, prediabetes, high LDL‐c, high TG, low HDL‐c and elevated ALT.

###### 

Summary of demographics and cardiometabolic risk factors for POWER and NHANES cohorts overall

  Co‐variate                      POWER   NHANES
  ------------------------------- ------- --------
  *N*                             1,823   617
  Female                          55.5%   50.2%
  15--17 Years old                41.1%   49.2%
  Race/Ethnicity                          
  Black/African American          20.6%   16.4%
  Hispanic/Latino                 26.4%   24.4%
  Other/Multiracial               10.9%   7.4%
  White                           42.2%   51.8%
  Insurance Type                          
  None                            0.8%    0.1%
  Private only                    31.2%   47.3%
  Public only                     57.3%   41.8%
  Private+Public                  0.0%    2.9%
  Unknown insurance               10.5%   0.0%
  Missing                         0.2%    7.9%
  Any insurance coverage          88.5%   92.1%
  Missing                         10.7%   0.2%
  BMI classification                      
  Class 1 obesity                 27.4%   62.9%
  Class 2 obesity                 35.7%   24.6%
  Class 3 obesity                 36.9%   12.5%
  Cardiometabolic variables               
  Non‐hypertensive                66.6%   91.5%
  Pre‐hypertension                11.5%   5.6%
  Hypertension                    20.0%   1.8%
  Missing                         1.9%    1.1%
  Prediabetes                     13.2%   10.3%
  Missing                         61.7%   70.3%
  Normal LDL                      32.0%   30.6%
  Borderline high LDL             5.9%    7.1%
  High LDL                        4.4%    2.0%
  Missing                         57.8%   60.3%
  Normal triglycerides            14.8%   23.6%
  Borderline high triglycerides   12.0%   7.8%
  High triglycerides              16.3%   8.4%
  Missing                         56.9%   60.3%
  Normal HDL‐c                    14.4%   17.1%
  Borderline low HDL‐c            9.9%    12.7%
  Low HDL‐c                       18.5%   12.4%
  Missing                         57.2%   57.8%
  Normal ALT                      24.7%   58.8%
  Moderate ALT elevation          24.1%   21.5%
  Severe ALT elevation            14.0%   9.5%
  Missing                         37.2%   10.2%

Values presented are weighted %. HDL‐c, HDL‐cholesterol; LDL, low‐density lipoprotein.

When comparing the mean differences of discrete values between POWER and NHANES (Table [3](#osp4166-tbl-0003){ref-type="table-wrap"}) while adjusting for age, sex, race/ethnicity, insurance status and multiple of the 95th BMI percentile, the POWER sample overall and for each of the three obesity classes had clinically and statistically higher systolic blood pressure, diastolic blood pressure and ALT and lower FG. Also, the POWER sample overall had higher TG and lower HDL‐c. The POWER and NHANES samples overall and in each of the obesity classes showed no consistent differences in TC, LDL‐c, fasting insulin and HOMA‐IR, or clinical differences in HbA1c.

###### 

Mean difference between POWER and NHANES adjusted for sex, age, race/ethnicity (African American, Asian/Other, Latino/Hispanic and White), insurance status (Private or Private+Public, Public or None, Missing or Unknown) and multiple of the 95th BMI percentile for all subjects and each obesity class

  Outcome                     POWER mean (SD)   NHANES mean (SD)   Adjusted mean difference (POWER‐NHANES) (95% CI)   *P*‐value
  --------------------------- ----------------- ------------------ -------------------------------------------------- -----------
  All subjects                                                                                                        
  Systolic BP (mm Hg)         118.9 (12.1)      111.1 (10.2)       6.5 (5.5, 7.6)                                     \<0.001
  Systolic BP percentile      67.8 (26.5)       46.9 (26.4)        17.3 (14.5, 20)                                    \<0.001
  Diastolic BP (mm Hg)        69.1 (9.9)        57.7 (13.9)        10.1 (8.8, 11.4)                                   \<0.001
  Diastolic BP percentile     60 (25.1)         34.6 (26.8)        21.9 (19.1, 24.7)                                  \<0.001
  HbA1c (%)                   5.4 (0.4)         5.3 (0.3)          0.1 (0, 0.1)                                       0.038
  Fasting glucose (mg/dL)     89.3 (8.8)        95.7 (7.1)         −6.9 (−8.2, −5.6)                                  \<0.001
  Fasting insulin (uU/mL)     26 (23)           24.9 (13.4)        −2.3 (−5.1, 0.6)                                   0.117
  HOMA‐IR                     5.8 (5.2)         5.9 (3.4)          −0.9 (−1.6, −0.2)                                  0.014
  Total cholesterol (mg/dL)   159.4 (35.6)      155.6 (28.3)       3.6 (−1.1, 8.2)                                    0.131
  LDL‐c (mg/dL)               92.5 (29.8)       90.9 (24.7)        0.8 (−3.3, 4.9)                                    0.707
  Triglycerides (mg/dL)       131.9 (81.3)      95.6 (59.2)        33.6 (22.9, 44.3)                                  \<0.001
  HDL‐c (mg/dL)               42 (10.5)         45.7 (9.6)         −2.4 (−3.9, −0.9)                                  0.002
  Non‐HDL‐c (mg/dL)           117.3 (36.1)      109.9 (28)         5.9 (1.3, 10.4)                                    0.012
  ALT (U/L)                   33.4 (29)         24.2 (19.1)        7.8 (5.5, 10.1)                                    \<0.001
  Class 1 obesity                                                                                                     
  Systolic BP (mm Hg)         115.7 (11.8)      109.7 (9.8)        6.7 (5.2, 8.3)                                     \<0.001
  Systolic BP percentile      62.4 (27.5)       43.5 (26.3)        18.9 (14.8, 23)                                    \<0.001
  Diastolic BP (mm Hg)        66.9 (9.6)        56.9 (13.8)        10.4 (8.4, 12.3)                                   \<0.001
  Diastolic BP percentile     54.9 (25)         32.6 (26.1)        21.9 (17.9, 26)                                    \<0.001
  HbA1c (%)                   5.3 (0.3)         5.3 (0.3)          0.1 (0, 0.2)                                       0.062
  Fasting glucose (mg/dL)     88.6 (8.5)        94.6 (7)           −6.2 (−8.1, −4.3)                                  \<0.001
  Fasting insulin (uU/mL)     20.9 (22.4)       19.7 (8.3)         0.2 (−4.2, 4.5)                                    0.939
  HOMA‐IR                     4.7 (5.2)         4.6 (2.1)          −0.2 (−1.2, 0.8)                                   0.710
  Total cholesterol (mg/dL)   158.7 (34.8)      153.9 (27.5)       4.4 (−2.2, 11)                                     0.190
  LDL‐c (mg/dL)               91.1 (29.9)       87.6 (23.9)        3.5 (−2.5, 9.6)                                    0.255
  Triglycerides (mg/dL)       133.5 (85.6)      97.3 (62.4)        32.3 (15.7, 48.8)                                  \<0.001
  HDL‐c (mg/dL)               43 (10.2)         46.5 (9.6)         −2.8 (−4.9, −0.7)                                  0.010
  Non‐HDL‐c (mg/dL)           115.5 (35.9)      107.4 (27.8)       6.9 (0.3, 13.6)                                    0.041
  ALT (U/L)                   28.7 (20.1)       22.8 (20.8)        5.7 (2.1, 9.3)                                     0.002
  Class 2 obesity                                                                                                     
  Systolic BP (mm Hg)         117.5 (10.5)      111.4 (10.5)       6.6 (4.8, 8.5)                                     \<0.001
  Systolic BP percentile      65.5 (25.8)       47.4 (25.2)        17.8 (13, 22.6)                                    \<0.001
  Diastolic BP (mm Hg)        68.2 (9.3)        57.6 (13.4)        10.7 (8.4, 13.1)                                   \<0.001
  Diastolic BP percentile     58.4 (24.7)       33.9 (26.4)        24.5 (19.5, 29.5)                                  \<0.001
  HbA1c (%)                   5.4 (0.4)         5.3 (0.3)          0.1 (0, 0.2)                                       0.014
  Fasting glucose (mg/dL)     89.3 (8.1)        98.2 (7.6)         −8.2 (−10.7, −5.8)                                 \<0.001
  Fasting insulin (uU/mL)     23.2 (15.9)       31.7 (15.8)        −7.5 (−12.5, −2.5)                                 0.004
  HOMA‐IR                     5.1 (3.7)         7.8 (4.3)          −2.3 (−3.7, −1)                                    \<0.001
  Total cholesterol (mg/dL)   163.7 (39.1)      159.1 (30.9)       3.8 (−4.9, 12.5)                                   0.396
  LDL‐c (mg/dL)               94.8 (32)         96.5 (26.7)        −1.9 (−9.2, 5.4)                                   0.607
  Triglycerides (mg/dL)       133 (88.6)        88.7 (42.1)        42 (27.8, 56.3)                                    \<0.001
  HDL‐c (mg/dL)               42.6 (10)         45.2 (10.2)        −2.8 (−5.6, 0)                                     0.053
  Non‐HDL‐c (mg/dL)           120.7 (40)        113.9 (29.9)       6.2 (−2.2, 14.7)                                   0.149
  ALT (U/L)                   34 (29.3)         26.1 (16)          8.4 (5.1, 11.7)                                    \<0.001
  Class 3 obesity                                                                                                     
  Systolic BP (mm Hg)         122.6 (12.7)      116.1 (10)         5.8 (3.6, 8.1)                                     \<0.001
  Systolic BP percentile      74.1 (25.2)       59.4 (25.4)        11.3 (5.2, 17.5)                                   \<0.001
  Diastolic BP (mm Hg)        71.5 (10.3)       61.3 (14.8)        9.2 (5.8, 12.6)                                    \<0.001
  Diastolic BP percentile     65.3 (24.4)       44.3 (28.2)        18 (11.2, 24.8)                                    \<0.001
  HbA1c (%)                   5.4 (0.4)         5.5 (0.3)          −0.1 (−0.2, 0)                                     0.123
  Fasting glucose (mg/dL)     90 (9.6)          96 (5.6)           −7.5 (−10, −4.9)                                   \<0.001
  Fasting insulin (uU/mL)     33.6 (27.7)       32.6 (15.3)        −0.4 (−9.3, 8.4)                                   0.923
  HOMA‐IR                     7.4 (6.1)         7.7 (3.5)          −0.6 (−2.5, 1.4)                                   0.576
  Total cholesterol (mg/dL)   155.8 (31.9)      156.8 (26)         −0.9 (−11.1, 9.4)                                  0.871
  LDL‐c (mg/dL)               91.4 (27.1)       94.1 (21.7)        −2.6 (−11, 5.8)                                    0.541
  Triglycerides (mg/dL)       129.2 (68.6)      101.5 (70.1)       21.6 (−3.8, 46.9)                                  0.097
  HDL‐c (mg/dL)               40.5 (11.1)       42.7 (7.7)         −1 (−4.3, 2.3)                                     0.556
  Non‐HDL‐c (mg/dL)           115.5 (31.4)      114.1 (24.2)       0.4 (−8.7, 9.5)                                    0.937
  ALT (U/L)                   36.5 (33.6)       27 (16.1)          9 (4.4, 13.6)                                      \<0.001

BMI, body mass index; BP, blood pressure; HbA1c, hemoglobin A1c; HOMA‐IR, homeostasis model assessment‐insulin resistance; HDL‐c, HDL‐cholesterol; LDL‐c, LDL‐cholesterol; NHANES, National Health and Nutrition Examination Survey; POWER, Pediatric Obesity and Weight Evaluation Registry.

The odds of meeting criteria for hypertension was 8.72 times higher (*p* \< 0.001) for those in POWER compared with NHANES. The odds of having high triglycerides, low HDL‐c or high ALT were each approximately twice as high for the POWER participants compared with the NHANES participants. The odds of having high LDL‐c or prediabetes was not statistically different between groups (Table [4](#osp4166-tbl-0004){ref-type="table-wrap"}).

###### 

Odds ratios between NHANES and POWER adjusted for sex, race/ethnicity (African American, Asian/Other, Latino/Hispanic and White), insurance status (Private or Private+Public, Public or None, Missing or Unknown) and multiple of the 95th BMI percentile for all subjects and each obesity class

  Outcome                     POWER (%)   NHANES (%)   Adjusted odds ratio (95% CI)   *P*‐value
  --------------------------- ----------- ------------ ------------------------------ -----------
  All subjects                                                                        
  Hypertension criteria met   20.4        2.2          8.60 (4.66, 15.86)             \<0.001
  Prediabetes                 34.4        40.0         0.78 (0.53, 1.14)              0.202
  High LDL                    10.4        5.5          1.71 (0.90, 3.23)              0.101
  High triglycerides          38.0        20.3         2.17 (1.44, 3.26)              \<0.001
  Low HDL                     43.3        25.5         1.76 (1.23, 2.52)              0.002
  High ALT                    22.3        9.6          2.56 (1.76, 3.72)              \<0.001
  Class 1 obesity                                                                     
  Hypertension criteria met   13.8        1.4          12.16 (4.31, 34.31)            \<0.001
  Prediabetes                 27.7        30.3         0.81 (0.45, 1.47)              0.494
  High LDL                    10.5        4.5          2.21 (0.82, 5.97)              0.117
  High triglycerides          38.2        22.2         2.09 (1.20, 3.62)              0.009
  Low HDL                     38.6        22.4         1.94 (1.17, 3.24)              0.011
  High ALT                    15.7        7.5          2.06 (1.13, 3.74)              0.018
  Class 2 obesity                                                                     
  Hypertension criteria met   16.0        2.1          9.99 (2.95, 33.83)             \<0.001
  Prediabetes                 32.4        49.6         0.75 (0.37, 1.51)              0.415
  High LDL                    10.8        9.7          0.84 (0.32, 2.25)              0.734
  High triglycerides          34.9        14.1         3.06 (1.45, 6.47)              0.004
  Low HDL                     40.3        26.0         1.86 (0.99, 3.48)              0.055
  High ALT                    21.7        12.6         2.38 (1.31, 4.31)              0.005
  Class 3 obesity                                                                     
  Hypertension criteria met   29.4        5.8          5.02 (1.90, 13.31)             0.001
  Prediabetes                 41.8        56.2         0.56 (0.25, 1.23)              0.150
  High LDL                    9.8         2.3          4.09 (0.73, 23.03)             0.111
  High triglycerides          40.9        23.6         1.76 (0.71, 4.39)              0.227
  Low HDL                     50.6        38.0         1.42 (0.62, 3.22)              0.406
  High ALT                    27.9        13.0         2.72 (1.25, 5.93)              0.012

CI, confidence interval; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; NHANES, National Health and Nutrition Examination Survey; POWER, Pediatric Obesity and Weight Evaluation Registry.

Discussion {#osp4166-sec-0012}
==========

In comparing the cardiometabolic profiles between a treatment‐seeking sample of youth with obesity and a population sample of youth with obesity, only TC, LDL‐c, HbA1c, insulin and HOMA‐IR were similar between these two samples, even when adjusting for BMI and demographics. The treatment‐seeking youth with obesity had higher TG, lower HDL‐c, higher blood pressure and higher ALT compared with the population sample of youth with obesity. Paradoxically, treatment‐seeking youth had *lower* FG. These differences remained consistent, for the most part, when youth were separated into different categories of degree of obesity.

In the general pediatric population and even in the context of obesity, high LDL‐c is rare and is usually related to familial hypercholesterolemia; thus, the lack of difference in LDL‐c between the treatment‐seeking sample and the population sample of youth with obesity is not surprising. However, because the aetiology of high TG and low HDL‐c *is* often related to adiposity, comparable levels of TG and HDL‐c between the treatment‐seeking and population cohorts were expected when adjusting for BMI. The unexpectedly identified differences may be related to a referral bias in that the American Academy of Pediatrics recommends screening for dyslipidemia in children with obesity [1](#osp4166-bib-0001){ref-type="ref"} and abnormal results may have served as a prompt for referral to a pediatric weight management program.

The prevalence of hypertension in the general population of youth is approximately 2--4% [14](#osp4166-bib-0014){ref-type="ref"}. Yet, in this study of youth with obesity, the population cohort prevalence was only 1.8% and substantially more in the treatment‐seeking sample at 20%. While obesity is associated with elevated blood pressure, the Bogalusa Heart Study, a large longitudinal study of cardiovascular disease risk factors in youth, found that the correlation between BMI and blood pressure was only 0.3 [15](#osp4166-bib-0015){ref-type="ref"}. Thus, other unmeasured variables are likely contributing to the high blood pressure in the treatment‐seeking group or perhaps these patients represent a different phenotype of children with obesity who have particularly adverse metabolic profiles including high blood pressure [16](#osp4166-bib-0016){ref-type="ref"}. Additionally, there may be more "white coat hypertension" in the treatment‐seeking group compared with the population‐based sample or there may be more technical difficulties related to measuring blood pressure in the clinical setting (such as cuff‐size) which may not be present in the more standardized, research setting. Finally, the higher prevalence of hypertension in the treatment‐seeking cohort may also be related to referral bias as, similar to dyslipidemia screening, the American Academy of Pediatrics recommends universal screening for elevated blood pressure [17](#osp4166-bib-0017){ref-type="ref"}.

Regarding the diabetes risk lab tests, no discernible or clinically meaningful differences in HbA1c, insulin, HOMA‐IR or diagnosis of prediabetes (impaired FG or borderline HbA1c) between groups were identified, as hypothesized. In contrast to these findings, lower FG levels in the treatment‐seeking sample of children were observed. The explanation for this finding is unclear and cannot be determined from this study. Speculatively, this finding could be related to differences in Tanner stage between cohorts, which is known to influence insulin and glucose metabolism [18](#osp4166-bib-0018){ref-type="ref"}. Moreover, this finding could be spurious as large population‐based studies are conflicted as to whether using FG or HbA1c is the most appropriate metric for determining prediabetes/diabetes risk and prevalence [19](#osp4166-bib-0019){ref-type="ref"}. Finally, the differences in FG levels may be related to differences in the laboratory analysis methods between the two cohorts. While the NHANES laboratory methods are standardized, the POWER methods are not.

Elevated ALT, which has its limitations in that it under estimates liver pathology in youth [12](#osp4166-bib-0012){ref-type="ref"}, [20](#osp4166-bib-0020){ref-type="ref"}, is nonetheless a clinically relevant marker of nonalcoholic fatty liver disease (NAFLD). Youth with obesity and severe obesity often present with NAFLD (38--65%) at higher prevalence rates than in the general population (13%) as defined by liver biopsy [21](#osp4166-bib-0021){ref-type="ref"}, [22](#osp4166-bib-0022){ref-type="ref"}. Thus, while treatment‐seeking youth had consistently higher ALT than the population‐based sample, both samples likely have much higher prevalence rates of NAFLD than was suggested by their ALT.

Although this treatment‐seeking cohort of youth with obesity had an overall worse cardiometabolic profile compared with the population‐based sample of youth with obesity, the profiles of these treatment seekers are similar to other treatment‐seeking cohorts from around the world. For example, a large survey of 26,008 children (mean age 12.6 years, 56% girls, mean BMI 29.4 kg/m^2^) with overweight (BMI \> 90th percentile) or obesity (\>97th percentile) who were treated in any of 98 weight management treatment centers from Germany, Austria and Switzerland examined the cardiometabolic status in these patients [23](#osp4166-bib-0023){ref-type="ref"}. Among the subgroup of patients with BMI \> 99.5 percentile, the hypertension prevalence was nearly 45%, low HDL‐c prevalence was 15% and high triglyceride prevalence was 17%.

The hypothesis for this study was that treatment‐seeking youth with obesity and youth with obesity from the general population would have similarly poor cardiometabolic profiles when adjusting for BMI. This finding would have served as a "call to action" for more availability of weight management programs given the enormous number of youth with obesity who are not receiving obesity treatment. However, overall, the results were not consistent with this hypothesis. The reasons for the presence of differences in cardiometabolic profiles between treatment‐seeking and population obesity are unclear but could be related to any number of unmeasured confounding variables. One of these variables, which may be especially relevant, is mental illness. Rates of mental illness are known to be higher among treatment‐seeking youth with obesity compared with the general population of youth with obesity [4](#osp4166-bib-0004){ref-type="ref"}, [5](#osp4166-bib-0005){ref-type="ref"}, [6](#osp4166-bib-0006){ref-type="ref"}, and mental illness also has adverse effects on cardiometabolic health [24](#osp4166-bib-0024){ref-type="ref"}. Future studies should include measurements of mental illness as a potential moderator of the association between treatment‐seeking status and poor cardiometabolic health.

Strengths of this study include the large sample size, nationally representative nature of both cohorts and generalizability of findings due to the racial/ethnic and gender distributions of the cohorts. Limitations of this study include methods of data collection were not uniform across the pediatric weight management clinics/programs used in the treatment‐seeking sample and the amount of missing data. Also, confounding variables such as diet, physical activity, pubertal status, emotional stress/mental illness and direct measures of adiposity (particularly visceral adiposity) were not available for measurement. All of these factors, each to a variable degree, may be associated with cardiovascular disease risk factors and with obesity status. As stated earlier, referral bias may also account for some of the differences in cardiometabolic profiles between the treatment‐seeking and population cohorts of youth with obesity. Specifically, it may be that those with comorbidities are more likely to be seen in weight management clinics. This bias would be exacerbated if weight management clinics require the presence of comorbidities as a prerequisite for referral. However, a survey of the programs included in POWER identified that 56% of the programs required potential patients to have a BMI \> 85th percentile before enrolling and 36% of the programs required potential patients to have a BMI \>95th percentile. Only 8% required the additional presence of a comorbid condition [7](#osp4166-bib-0007){ref-type="ref"}. Indeed, the American Academy of Pediatrics recommends that patients with obesity should be referred to multidisciplinary weight management programs when there is no weight loss achieved with less structured weight management interventions. The comorbidity status alone is not an indication for referral [1](#osp4166-bib-0001){ref-type="ref"}. Finally, the sample sizes of youth with classes II and III obesity in the treatment‐seeking cohort were much larger than the population cohort which may have affected the outcomes.

Conclusion {#osp4166-sec-0013}
==========

In general, the prevalence of cardiometabolic risk factors increases with the degree of obesity in children and adolescents [25](#osp4166-bib-0025){ref-type="ref"}. However, this study demonstrated that for a given BMI, obesity treatment‐seeking youth are more adversely affected by these risk factors than the general population of youth with obesity. This suggests that youth who are receiving care in multicomponent pediatric weight management clinics/programs may represent a distinct group that is at particularly high risk for the development of future cardiometabolic disease. Identification of factors contributing to the more adverse cardiometabolic profiles may provide insight into effective treatments.
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